single5MG
Selank
5MG Protocol
Selank 5MG
Injection Freq.
Inject once daily
Cycle Sched.
Daily subcutaneous injections for 4-week cycles with 4-week breaks (8–16 weeks total protocol)
Reconstitution
3.0 mL BAC water
Anxiolytic effects comparable to benzodiazepines in cited human trials
Anti-asthenic (energy-supporting) benefits alongside anxiety reduction
Non-sedating
low dependence risk described
Long-lasting neurobehavioral stabilization observed in primate studies
Generally well tolerated in reported courses
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 300 mcg | 18 |
| 2 | Weeks 3–4 | 500 mcg | 30 |
Inject once daily
Daily subcutaneous injections for 4-week cycles with 4-week breaks (8–16 weeks total protocol)
Selank is a tuftsin-analog peptide described as combining anxiolytic effects with an anti-asthenic (energy-supporting) profile. The protocol notes Russian clinical-trial experience in anxiety disorders and neurasthenia, where Selank is reported to produce anxiety reduction comparable to benzodiazepines but without sedation or dependence potential—features that make it suitable for daytime use in research and clinical observation. The page also summarizes preclinical work: in primates, intranasal Selank is described as eliminating fear/anxiety behaviors with longer-term stabilization of neurobehavioral patterns, while rodent models report efficacy similar to classical tranquilizers. Although intranasal use dominates published human literature, the protocol indicates that subcutaneous administration is used in research settings for consistent absorption and easier measurement. Overall, Selank is positioned as a non-sedating anxiolytic peptide with favorable tolerability and functional benefits.
Occasional mild injection-site reactions (redness/minor irritation)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)